 The main purpose of this study is to determine the safety of using the combination of decitabine and a cancer vaccine plus Hiltonol. The vaccine will be made from the subjects blood cells and is designed to interact in the subjects body with cells that are programmed to fight specific tumor proteins called NY-ESO-1, MAGE-A1 and MAGE-A3. The decitabine will be given to increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. Subjects will be assessed to determine how these tumors respond to the treatment. 